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Influence of ejection fraction
on cause-specific mortality in
heart failure with preserved
ejection fraction
Left ventricular ejection fraction (LVEF) is
an important predictor of cardiovascular
(CV) mortality in patients with heart failure
(HF), and cause of death varies with ejection
fraction.1–3 Nevertheless, the influence of
LVEF on cause-specific death in HF with
preserved ejection fraction (HFpEF) patients
is not well described.
Figure 1 Age- and sex-adjusted annualized incidence of components of death by left
ventricular ejection fraction in TOPCAT-Americas. CV, cardiovascular; MI, myocardial
infarction.
We evaluated the influence of LVEF on CV
and non-CV deaths in the Treatment of Pre-
served Cardiac Function Heart Failure with
an Aldosterone Antagonist (TOPCAT) study.
The TOPCAT trial enrolled HFpEF patients
with LVEF ≥45% and assessed the effect of
spironolactone on a composite outcome of
CV death, aborted cardiac arrest, and hospi-
talization for HF, over a median follow-up of
42 months.4 LVEF was determined at each site
by echocardiography (96.7%), radionuclide
ventriculography (2.3%), or angiography (1%).
All endpoints were adjudicated centrally by
a blinded clinical endpoint committee. Deaths
were classified into three categories: CV,
non-CV, and unknown. Cardiovascular deaths
were further classified as sudden cardiac
death (SCD), and death due to myocardial
infarction (MI), pump failure, stroke, or
another CV cause. Death was considered
non-CV if an unequivocal and documented
non-CV cause could be established as the
primary cause of death. Cause of death
was considered unknown when insufficient
data were available to determine the rea-
son to be CV or non-CV.5 We divided the
range of LVEFs across the entire TOPCAT
trial into four separate categories: ≤47%,
48–52%, 53–57%, and ≥58%. Each of these
categories was centered around a multiple
of 5, as we observed a substantial ‘digit
preference’ for LVEF values in multiples of
5, which has been seen in previous trials.2
Baseline characteristics were summarized for
each group, and compared using trend tests.
Unadjusted and age/sex-adjusted incidence
rates of cause-specific mortality were calcu-
lated across LVEF categories using Poisson
regression models. The incident rates and
proportions of cause-specific death were
compared between the lowest LVEF category
vs. others. All these analyses were conducted
in the Americas (n= 1767) owing to previ-
ously noted substantial regional differences
in patient demographics, outcomes, and
response to spironolactone in the TOPCAT
trial.6
Among patients enrolled in Americas,
LVEF ranged from 44% to 85% (mean 58%,
median 58%, 25th-75th percentile 53–61%).
Baseline characteristics varied considerably
by LVEF. Patients in higher LVEF categories
were older, more likely to be female, and have
a history of hypertension, and less likely to be
current smokers or have a history of MI, per-
cutaneous coronary intervention, coronary
artery bypass graft surgery, or be on beta-
blocker, angiotensin-converting enzyme
inhibitor/angiotensin receptor blocker, than
those with lower LVEFs (all P< 0.05). The
crude and age/sex-adjusted annualized rates
of all-cause mortality, CV mortality and SCD
were highest in the lowest LVEF category
as compared to other categories (P< 0.001
for all components). Crude and age/sex-
adjusted annualized rates of pump failure, MI
related, stroke related, non-CV death and
unexplained death did not vary across LVEF
categories (Figure 1). However, compared
to patients with LVEF ≥48%, the proportion
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of SCD in the lowest LVEF category was
significantly higher (33% vs. 17%, P= 0.007)
and numerically higher for CV death (69% vs.
56%, P= 0.11) and lower for non-CV death
(22% vs. 33%, P= 0.13).
The cause-specific breakdown of CV and
non-CV death was not reported by earlier
smaller randomized controlled trials (RCTs)
among (DIG-ancillary and PEP-CHF) HFpEF
patients; the more recent RCTs including
TOPCAT and I-PRESERVE have reported
these details on the mode of death among
enrolled patients. Most HFpEF patients in
these RCTs die of CV causes (60–70%) but
none of the recent RCTs have evaluated the
influence of LVEF on cause-specific deaths.
We have shown that the rates of cause-
specific mortality in HFpEF patients vary by
LVEF. The differences in cause of death across
the LVEF spectrum in this HFpEF popula-
tion may in part be explained by substantial
variation in baseline characteristics across
LVEF categories. HFpEF patients with lower
LVEF had a higher proportion of coronary
artery disease history and behaved more like
HF with reduced ejection fraction, perhaps
accounting for higher rates of CV death and
SCD in lower-LVEF HFpEF patients. On the
other hand, patients in the higher LVEF cate-
gories had a lower burden of CV morbidities,
thus explaining the higher proportion of
non-CV deaths in these individuals. The pro-
portion of deaths attributable to pump failure
were quite low, while not unexpected, have
potential implications for future investigation
of non-HF therapies among these patients.
Our analyses have several limitations.
LVEFs were measured at the sites in TOP-
CAT and verified on a fraction of enrolled
subjects (27%) by the core laboratory. The
core lab LVEFs were significantly greater by
∼1.6 units than site reported LVEFs. There
is substantial geographic variation in baseline
characteristics and event rates in TOPCAT
among patients enrolled in Russia and the
Republic of Georgia as compared to the
Americas.6,7 Therefore, we have restricted
these analyses to the Americas, in which we
are more certain of the diagnosis of HF.
In summary, we found that baseline char-
acteristics and event rates of cause-specific
mortality in HFpEF vary by LVEF. These
findings may have implications for future trials
in HFpEF as the burden of disease modifiable
by specific therapies may vary by LVEF.
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